Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 13/20 | 0.58 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398561 | 1.00 | ENPP1 (0.58) | ENPP1NSD2EGFRKDM4ELMNA | |
| SCHEMBL20305205 | 0.77 | ENPP1 (0.92) | ENPP1MAPK1 | |
| SCHEMBL23762362 | 0.74 | ENPP1 (0.60) | ENPP1 | |
| SCHEMBL23762245 | 0.73 | ENPP1 (1.00) | ENPP1MAPK1 | |
| Hydrochloric Acid SCHEMBL23727275 | 0.73 | ENPP1 (0.59) | ENPP1 | |
| SCHEMBL11857812 | 0.73 | ENPP1 (0.73) | ENPP1EGFRKDM4ELMNAHPGD | |
| SCHEMBL20305103 | 0.73 | ENPP1 (0.72) | ENPP1MAPK1 | |
| SCHEMBL23762284 | 0.72 | ENPP1 (1.00) | ENPP1EGFRKDM4ELMNAHPGD | |
| Hydrochloric Acid SCHEMBL30080035 | 0.72 | ENPP1 (0.75) | ENPP1EGFRKDM4ELMNAHPGD | |
| SCHEMBL23762286 | 0.72 | ENPP1 (0.95) | ENPP1EGFRKDM4ELMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2022-02-24 | — | — | US | disclosed |
| EP-3902787-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | Riboscience LLC (US) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020140001-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2020-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, PDE7A | ENPP1 1/4885NSD2 3728/4885EGFR 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.